Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NSC105808 is a small molecule research compound identified as a specific inhibitor of the DNA2 nuclease/helicase. DNA2 is a multifunctional enzyme that plays a critical role in maintaining genomic stability through its involvement in DNA replication (specifically Okazaki fragment maturation) and various DNA repair pathways, including double-strand break repair and the recovery of stalled replication forks. By specifically targeting the nuclease activity of DNA2, NSC105808 disrupts these essential genomic maintenance processes, leading to increased replication stress, DNA damage accumulation, and apoptosis in cancer cells. Preclinical studies have demonstrated that NSC105808 possesses potent antitumor activity and can sensitize cancer cells to other DNA-damaging agents, making it a valuable chemical probe for studying DNA2 biology and a potential lead for cancer therapeutic development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NSC105808.